ReviewCurrent diabetes reviews2026
COVID-19 Impact on Lipid Profile and Metabolome in Patients with Type 2 Diabetes Mellitus: Mini-Review.
Review in Current diabetes reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis review aims to explore the pathophysiological mechanisms by which SARS-- CoV-2 affects lipid metabolism and the metabolome in patients with Type 2 Diabetes Mellitus (T2DM). It compares these alterations with those observed in non-diabetic individuals and proposes strategies to mitigate potential long-term metabolic complications.
methodsA narrative review was conducted using PubMed, Scopus, and Google Scholar to identify studies published between 2004 and 2025 concerning adult T2DM patients during or after COVID-19 infection. The analysis focused on lipid profiles, including total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides, along with hemoglobin A1C levels and COVID-19 severity. Search terms included: (Post-COVID-19) AND (Diabetes Mellitus Type 2), ((Post-COVID-19) AND (Diabetes Mellitus Type 2)) AND (Lipid Profile), ((- COVID-19) AND (Lipid Profile)) AND (Diabetes Mellitus Type 2), (Post-COVID-19) AND (Lipid Metabolism), (COVID-19) AND (Lipid Metabolism), (Post-COVID-19) AND (Metabolome), (COVID-19) AND (Metabolome).
resultsPost-COVID-19, patients with T2DM exhibit persistent disturbances in lipid metabolism and broader metabolic pathways. SARS-CoV-2 infection amplifies metabolic dysregulation, leading to decreased levels of total cholesterol, HDL, and LDL, while triglyceride levels remain variable. Mechanistically, the virus disrupts lipid homeostasis by upregulating genes such as CD36 and peroxisome proliferator-activated receptor gamma (PPAR-γ) and by altering amino acid metabolism, particularly within the tryptophan-kynurenine and glutamine pathways. DISCUSSION: Enhanced oxidative stress and lipid peroxidation contribute to systemic inflammation and endothelial dysfunction. Furthermore, glycemic control worsens due to increased insulin resistance and pancreatic interactions involving angiotensin-converting enzyme 2 (ACE2).
conclusionCOVID-19 significantly alters lipid metabolism and the metabolomic profile in individuals with T2DM. Longitudinal studies are warranted to clarify the duration and clinical impact of these changes and to develop personalized therapeutic strategies for this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.